|Bid||0.00 x 4000|
|Ask||0.00 x 800|
|Day's Range||8.35 - 8.89|
|52 Week Range||3.69 - 24.00|
|Beta (3Y Monthly)||3.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.00|
What Are Analysts Recommending for VKTX and ENTA?(Continued from Prior Part)Growth drivers In November 2018, Viking Therapeutics (VKTX) issued a press release announcing positive results from its Phase 2 trial evaluating the efficacy of the 1-mg dose
What Are Analysts Recommending for VKTX and ENTA?Stock price movementOn April 12, Viking Therapeutics (VKTX) closed at $9.35, 6.22% lower than its previous closing price, 153.39% higher than its 52-week low of $3.69, and 61.04% below its 52-week
In addition, all nine patients in the 5 mg cohort experienced ≥ 30% reduction in liver fat and 77.8% were ‘super-responders’, defined as experiencing ≥ 50% reduction in liver fat. For those who may argue that the two patient populations are too dissimilar to offer a valid comparison, we believe that the very similar placebo responses seen in both outcomes in the table below indicate that the two populations are in fact quite similar.
Seven of nine patients getting Viking’s VK2809 at a dose of 5 milligrams once a day saw their liver fat cut by 50 percent or more. The biggest reduction in liver fat at the 5 milligram dose was 78 percent, according to data presented at the European Association for the Study of the Liver congress in Vienna. The company is also testing a 10 milligram dose.
Patients Receiving 5 mg Daily Doses of VK2809 Demonstrated Statistically Significant Median Reduction in Liver Fat Content of 53.8% 88% of Patients Receiving VK2809 Experienced ≥ 30% Reduction in Liver ...
Late-Breaker Presentation to Highlight Efficacy, Safety and Tolerability Results from 12-Week Phase 2 Trial Including New Data from Study's 5 mg Treatment Arm SAN DIEGO , April 4, 2019 /PRNewswire/ -- Viking ...
Every day this week the indices have opened on an upbeat note and then sold off. If you are interested in trading it the best approach is to wait at least 30 minutes to an hour after it opens and watch for a trading range to develop. The trading range provides a mechanism for risk control and nothing more.
SAN DIEGO , March 28, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 200.82% for Viking Therapeutics (VKTX) based on the company’s closing
Biotech stocks dominate our list of top charts to watch today. The stock is up over 50% this month, and over 400% since the start of the year, as investors await important clinical trial results on the company’s treatment for depression. Invitae Corp. (NVTA) rose 71 cents to $25.75 on 1.2 million shares Thursday.
Viking Therapeutics, Inc. (VKTX) is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. 1) VK2809, which is an oral, liver selective agonist of the thyroid hormone receptor beta (TRβ) and is being developed for the treatment of nonalcoholic steatohepatitis (NASH). • We anticipate the company conducting a pre-IND meeting with the FDA in mid-summer 2019 and a Phase 2b study in NASH patients to be initiated in the second half of 2019.
Conference call scheduled for 4:30 p.m. ET today - Additional VK2809 Phase 2 Data to be Presented at EASL 2019; Results Demonstrate Promising Efficacy at Doses as Low as 5 mg Daily - Initiation of Phase ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) shareholders might be concerned after seeing the share price drop 14% in the last quarter. But that doesn't change the fact that the returns over theRead More...
Conference Call Scheduled for Wednesday, March 13 at 4:30 p.m. Eastern Time SAN DIEGO , March 6, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
SAN DIEGO , Feb. 26, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / February 21, 2018 / The healthcare sector provides investors with some of the biggest profit opportunities in the whole market. An oversold stock in the sector we think you ...
CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. As a result of the advent of new technologies and product offerings in other industries, healthcare customers have come to expect the same experience from healthcare companies. ), AcelRx Pharmaceuticals Inc (ACRX), and Bio Blast Pharma Ltd (ORPN) represent four healthcare companies operating with the consumer's best interests in mind.